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OVERCOMING BARRIERS TO CARE for HEPATITIS C
Trends in Hepatitis C–Related Mortality, Liver Transplantation, and Treatment in the United States, 2002–2007.*
Year
Deaths to which 
 Hepatitis C Contributed
Transplantation for HCV- 
Related Primary Indication  
(Excluding Hepatoma)
Transplantation for 
HCV-Related and HBV- 
or HCV-Related HCC
Patients Treated with Antiviral 
 Therapy for Hepatitis C in U.S.
(95% CI)
no. of patients number number
2002 4839 1904 752 126,040 (125,449–126,649)
2003 4616 1862 829 144,276 (143,616–144,943)
2004 4586 2022 889 107,131 (106,653–107,614)
2005 4767 2040 988 114,197 (113,580–114,823)
2006 6415 1942 1149 88,083 (87,685–88,486)
2007 6572 1799 1247 83,270 (82,897–83,647)
* Data in the column on mortality are from the Centers for Disease Control and Prevention, National Center for Health Statistics, 
Multiple Cause of Death 1999–2009 (http://wonder.cdc.gov/mcd-icd10.html), and are based on hepatitis C infection (ICD-10, 
17.1 and 18.2) declared as a contributing cause on the death certificate; data in the columns on transplantation are from the 
Organ Procurement and Transplantation Network (as of May 2012); and data in the column on antiretroviral therapy are from 
Volk et al.3 CI denotes confidence interval, HBV hepatitis B virus, HCC hepatocellular carcinoma, and HCV hepatitis C virus.
Thanks to steady scientific and therapeutic advances related 
to hepatitis C virus (HCV), now 
is a time of much optimism re-
garding the care of HCV-infected 
patients.1 Many seminal develop-
ments have been documented, 
and the number of new agents 
and regimens being studied in 
clinical trials suggests that gains 
will continue to be made in the 
tolerability and efficacy of treat-
ments for HCV infection.1 These 
advances raise the hope that we 
may overcome the barriers creat-
ed by the relatively poor efficacy 
and tolerability of peg interferon 
alfa plus ribavirin, the historical 
backbone of treatment in hepati-
tis C. Although optimism is justi-
fied, so is some degree of cau-
tion, for as treatment improves, 
the true rate-limiting factor in 
achieving better outcomes may 
turn out to be access to diagno-
sis and treatment.
To better understand progress 
in the care of patients with hepa-
titis C, one must consider the 
populations we treat and the 
health system context in which 
we treat them. According to a 
2010 strategic report from the 
Institute of Medicine (IOM),2 lack 
of knowledge and awareness on 
the part of health care providers, 
persons at risk for infection, 
health policymakers, and the 
public contributes to the risk of 
ongoing transmission and lost 
opportunities for diagnosis, treat-
ment, and prevention. Although 
therapy that has limited efficacy 
and harsh side effects provides 
minimal incentive for patients 
and clinicians to pursue diagno-
sis and treatment, the greatest 
barrier to treatment is lack of di-
agnosis: estimates suggest that 
about half of the approximately 
3.2 million Americans infected 
with HCV are unaware of their 
infection, and only a tiny frac-
tion are treated (see table).3,4 At 
the population level, this low 
rate of disease detection limits 
the possibility that new therapies 
can deliver potential downstream 
economic and public health ben-
efits of the interruption of in-
creases in HCV-related mortality 
and in liver transplantation for 
such complications of HCV in-
fection as end-stage liver disease 
and hepatocellular carcinoma.
The challenge of improved di-
agnosis and treatment is made 
more acute by the disproportion-
ate distribution of the burden of 
hepatitis C among vulnerable 
groups. The risk of HCV infec-
tion is highest among blacks and 
Hispanics, people with lower lev-
els of education, and the poor.4 
Analysis of data from the National 
Health and Nutrition Examination 
Survey (NHANES) indicates that 
as compared with non-Hispanic 
whites, non-Hispanic blacks have 
nearly twice the odds, and Mexi-
can Americans have more than 
two and a half times the odds, of 
having HCV antibodies. In addi-
tion, people with a family income 
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below the poverty line had nine 
times the odds of testing positive 
for HCV antibodies, as compared 
with people who had a household 
income two times the poverty 
threshold or higher.4 The IOM’s 
strategy report cites numerous 
studies indicating that whites 
are more likely than blacks to be 
evaluated for HCV infection and 
to undergo and complete treat-
ment for it, and there are similar 
disparities with regard to treat-
ment of, and mortality associ-
ated with, hepatocellular carci-
noma, a major complication of 
hepatitis C.2
According to another analysis 
of NHANES data, only margin-
ally more than one third of pa-
tients with hepatitis C who were 
medically eligible for treatment 
had private medical insurance.5 
In fact, infection with HCV was 
independently associated with the 
likelihood of being uninsured, 
even after adjustment for socio-
economic and demographic fac-
tors. Uninsured patients with hep-
atitis C may also be more likely 
to seek care in emergency rooms 
than in clinics or health centers 
— a finding that has important 
implications for programs aimed 
at improving diagnosis and treat-
ment in vulnerable groups.5
Taken together, these data sug-
gest that many people with hepa-
titis C may be at a disadvantage 
in terms of health literacy, which 
limits their capacity to success-
fully engage with health care ser-
vices to obtain a diagnosis and 
treatment. Engagement in the 
health system is a necessary 
though not sufficient condition 
for availing oneself of the bene-
fits from recent developments in 
therapy for hepatitis C.
In response to the IOM’s na-
tional strategy, the Department 
of Health and Human Services 
(DHHS) has developed a road map 
for education and care, focusing 
on disparities in health literacy 
and access to care, to better tar-
get programs for prevention, diag-
nosis, and treatment of viral hepa-
titis (www.hhs.gov/ash/initiatives/ 
hepatitis). If the Affordable Care 
Act assists patients in overcom-
ing constraints on access to 
treatment for hepatitis C, the pub-
lic health effect may be far more 
profound than that achievable 
with improved therapy alone.
What concrete measures might 
public health agencies take to im-
prove awareness, diagnosis, and 
treatment of hepatitis C? Efforts 
to increase community awareness 
are enhanced by targeting high-
priority populations with cultur-
ally sensitive and linguistically 
appropriate educational messages. 
Understanding community-spe-
cific epidemiologic factors facili-
tates the creation of programs 
tailored to settings with a high 
prevalence of HCV infection (e.g., 
correctional facilities) or groups 
with increased risk of transmis-
sion (e.g., injection drug users) 
or high prevalence (e.g., migrants 
from Egypt and some Southeast 
Asian countries). A successful ex-
ample of this approach is Stan-
ford University’s Jade Ribbon Cam-
paign to increase the detection 
of chronic hepatitis B and subse-
quent vaccination and treatment 
among Asian and Pacific Islander 
Americans. Of 1206 adults 
screened for chronic hepatitis B 
in its “3 For Life” pilot program, 
half showed no serologic evi-
dence of immunity, and 85% of 
these persons were then able to 
be vaccinated against hepatitis B.
On a population scale, the Cen-
ters for Disease Control and Pre-
vention has recently proposed a 
birth-cohort approach to screen-
ing for HCV — testing everyone 
born between 1945 and 1965 (an 
age group with increased risk of 
HCV exposure from the 1960s 
through the 1980s), rather than 
following the current risk-based 
screening recommendations (www 
.cdc.gov/Hepatitis/HCV/BirthCohort 
Testing.htm). Improved rates of re-
ferral to specialists for treatment 
depend not only on better patient 
awareness, but also on improved 
knowledge among primary care 
providers, which requires a great-
er focus on HCV in undergradu-
ate and postgraduate continuing 
medical education.
Finally, if such measures suc-
cessfully increase the rates of HCV 
detection, clinical questions re-
main. Do all HCV-infected per-
sons require treatment? Many will 
not have progressive liver injury 
leading to cirrhosis, and only a 
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Although therapy that has limited efficacy  
and harsh side effects provides minimal  
incentive for patients and clinicians to pursue  
diagnosis and treatment, the greatest barrier  
to treatment is lack of diagnosis: estimates 
suggest that about half of persons infected  
with HCV are unaware of their illness.
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minority will have hepatocellular 
carcinoma. Should the decision 
to treat be based on the risk of 
progressive liver disease or can-
cer, or simply on the presence of 
the infection? Historically, histo-
pathological evidence of inflam-
mation or fibrosis from liver biop-
sy was used to identify candidates 
for treatment, to improve the 
risk–benefit ratio associated with 
poorly efficacious, toxic, and ex-
pensive peginterferon alfa plus 
ribavirin therapy. Future regimens 
may be more efficacious and 
eventually less toxic but will sure-
ly be even more expensive. What 
clinical variables or biomarkers are 
sufficiently sensitive to identify pa-
tients at low risk for complications 
who may not need treatment? 
Does a more nuanced treatment 
approach dilute the simple mes-
sage of “detect and treat,” which 
resonates with many patients, 
clinicians, and the pharmaceuti-
cal industry?
The fragmentation and under-
funding of public health services 
reflect a health system that’s 
poorly positioned to improve the 
awareness, prevention, diagnosis, 
and treatment of hepatitis C — 
the necessary steps to interrupt-
ing the progress of this silent 
epidemic.2 We are at a critical 
juncture, determining whether, 
supported by health care reform, 
initiatives such as those suggest-
ed by the DHHS can translate the 
rhetoric of health disparities into 
better programs and outcomes 
for patients with hepatitis C. If 
the evolution in service delivery 
is successful, this may be a water-
shed moment not only for HCV 
therapeutics, but also for access 
to hepatitis treatment, improv-
ing care for all Americans infect-
ed with HCV.
Hepatitis C offers a window 
into contentious issues in health 
care reform. How can therapy be 
made more accessible, and if it is 
more accessible, how will we as a 
community pay for it? At a popu-
lation level, improving the diag-
nosis and treatment of HCV in-
fection will be expensive but will 
avert much illness and death 
from decompensated liver cirrho-
sis and hepatocellular carcinoma, 
the prevalence of which is pro-
jected to substantially increase 
over the next decade, at major 
cost to the community.2,3 The 
possibility of achieving future 
cost savings, particularly for dis-
advantaged groups, raises the 
question: can we afford not to 
improve the accessibility of treat-
ment for hepatitis C?
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
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Pathological Complete Response and Accelerated Drug 
Approval in Early Breast Cancer
Tatiana M. Prowell, M.D., and Richard Pazdur, M.D.
New drugs for breast cancer have historically been ap-
proved first for patients with 
metastatic disease who have few 
remaining options for systemic 
treatment. Approval for an adju-
vant indication occurs years lat-
er, after large, randomized trials 
with prolonged follow-up have 
been conducted in patients with 
early-stage disease. Recently, neo-
adjuvant trials have introduced 
new drugs preoperatively in pa-
tients with localized breast can-
cer. Such treatment aims to ren-
der locally advanced cancers 
operable, facilitate breast-con-
serving surgery, and ultimately 
improve survival. The rate of 
pathological complete response 
— absence of residual invasive 
cancer on pathological evalua-
tion of resected breast specimens 
and lymph nodes after preopera-
tive therapy — has been used as 
the primary end point in many 
neoadjuvant trials.
Promising investigational drugs 
should be incorporated into stan-
dard treatment for early-stage 
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